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Abstract
Background: The PI3K/Akt pathway is involved in cellular survival pathways by inhibiting apoptotic processes and
stimulating cell growth and proliferation. Its negative prognostic value has been proven in many types of cancer.
In soft tissue sarcomas, the expression profiles of the PI3K/Akt pathway components are poorly defined and their
significance uncertain. We aimed to investigate the prognostic impact of Akt (Akt1) phosphorylated at threonine
308
and serine
473, Akt2, Akt3, PI3K and PTEN, alone and in coexpression with ER and PgR in non-gastrointestinal
stromal tumor soft tissue sarcomas (non-GIST STSs).
Patients and methods: Tumor samples and clinical data from 249 patients with non-GIST STS were obtained, and
tissue microarrays (TMAs) were constructed. Immunohistochemistry (IHC) was used to evaluate marker expression
in tumor cells.
Results: In univariate analyses, the expression levels of p-Akt Thr
308 (P = 0.002), Akt2 (P = 0.008) and PI3K (P <
0.001) were significant prognostic factors. In the multivariate analysis, high PI3K expression was an independent
negative prognosticator (HR = 1.5, 95% CI = 1.0-2.2, P = 0.042) in addition to advanced age, tumor depth, high
malignancy grade, metastasis at diagnosis, surgery and positive resection margins. p-Akt Thr
308 expression had
strong unfavorable effect in men only (P = 0.009). In contrast, p-Akt Ser
473 expression had strong unfavorable
impact in women (P = 0.023). PgR-/p-Akt Ser
473+ phenotype tended to have less favorable impact in women (P =
0.087), but was the most favorable one in men (P = 0.010).
Conclusion: Expression of PI3K was significantly associated with aggressive behavior and shorter DSS in non-GIST
STSs. The site of Akt phosphorylation seems to have gender-dependent impact on survival in STS patients.
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Background
Soft tissue sarcomas (STS) are malignant tumors arising
from extraskeletal connective tissues. They are heteroge-
neous neoplasms, consisting of more than 50 subtypes,
and comprise less than 1% of adult malignancies [1,2].
Approximately 50% of the STS patients will succumb to
their disease because of metastasis or local progression
[3]. The prognostic factors determining tumor evolution
and ultimately patients’ fate include tumor grade, size,
location, depth, histological entity, positive resection
margins and presence of local relapse [4-10]. In addi-
tion, an array of recurrent gene aberrations are found to
be prognostic and predictive biomarkers in STSs
[11-13].
Akt is a serine/threonine protein kinase that exists in
three possible isoforms, including Akt1, Akt2, and Akt3.
Akt can be activated by phosphorylation at threonine
308
or at serine
473 for Akt1 or homologous sites for Akt2
and Akt3 by phosphatases which along with Akt iso-
forms, belong to the phosphoinositide 3-kinase (PI3K)/
Akt pathway. The PI3K/Akt pathway has been linked to
an extraordinarily diverse group of cellular functions,
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any medium, provided the original work is properly cited.including cell growth, proliferation, differentiation, moti-
lity, survival, intracellular trafficking and angiogenesis
[14]. Both PI3K and Akt isoforms have been implicated
as major players in many types of cancer [15-17].
The PI3K/Akt pathway seems to be more often
deregulated in cancer than any other pathway [18].
However, in the literature there is disagreement regard-
ing the prognostic impact of Akt expression. While the
majority of studies agree that Akt expression overtly
indicates a poor prognosis [19-21], there are several stu-
dies showing the opposite effect [22,23]. Expressions of
PI3K/Akt pathway components have rarely been investi-
gated in STSs and there are almost no studies devoted
to their prognostic value [24].
Different physiological function of the Akt family
k i n a s e si m p l i e st h a tt h ee x p r e s s i o no fi t si s o f o r m sm a y
also have different prognostic impact in cancer. The sig-
nificance of this variation for the survival of the STS
patients is not well investigated and it is not clear
whether the site of phosphorylation and the pattern of
expression can play prognostic roles.
In previous studies, we have shown the prognostic
value of female steroid hormone receptors in STSs, both
alone and in the coexpression with TGF-b and fascin
[25,26]. Such prognostic impact is not surprising, since
both ER and PgR regulate growth and cell differentiation
upon ligand-dependent and ligand-independent activa-
tion and are in essence growth factors. In this context
we wanted to explore the correlations between female
hormone receptors and the members of PI3K/Akt sig-
naling pathway. To our knowledge, these correlations
have not been described previously.
In this study, we investigate the prognostic impact of
all isoforms of Akt (phosphorylated at threonine
308 and
Akt phosphorylated at serine
473, non-phosphorylated
Akt2, and total Akt3), PI3K, PTEN, ER and PgR in 249
non-GIST STS patients. GIST cases were excluded from
the study since patients with this subtype of sarcoma
receive a specific treatment regimen which resulted in
significantly better survival.
Materials and methods
Patients and clinical samples
Primary tumor tissue from anonymized patients diag-
nosed with non-GIST STS at the University Hospital
of North Norway (UNN) 1973-2006 and The Hospitals
of Arkhangelsk region, Russia, were used in this retro-
spective study. In total, 496 patients were registered
from the hospital databases. Of these, 247 patients
were excluded due to missing clinical data (n = 86) or
inadequate material for histological examination (n =
161). Thus, 249 STS patients with full clinical records
and adequate paraffin-embedded tissue blocks were
eligible.
This report includes follow-up data as of September
2009. The median follow-up was 38 (range 0.1 - 392)
months. Formalin-fixed and paraffin-embedded tumor
specimens were obtained from the archives of the
Departments of Pathology at UNN and the Arkhangelsk
hospitals. The tumors were graded according to the
French Fèdèration Nationales des Centres de Lutte Con-
tre le Cancer (FNCLCC)[27].
Microarray construction
All sarcomas were histologically reviewed by two trained
pathologists (S.S. and A.V.) and the most representative
areas of viable tumor cells (neoplastic cells) were care-
fully selected and marked on the hematoxylin and eosin
(H&E)-stained slides and sampled for the tissue micro-
array blocks (TMAs). The TMAs were assembled using
a tissue-arraying instrument (Beecher Instruments, Sil-
ver Springs, MD). The Detailed methodology has been
previously reported [28]. Briefly, we used a 0.6 mm dia-
meter stylet, and the study specimens were routinely
sampled with two replicate core samples (different
areas) of neoplastic tissue. To include all core samples,
12 tissue array blocks were constructed. Multiple 4-μm
sections were cut with a Micron microtome (HM355S)
and stained using specific antibodies for immunohisto-
chemistry (IHC) analyses.
Immunohistochemistry (IHC)
The applied antibodies were subjected to in-house vali-
dation by the manufacturer for IHC analysis on paraf-
fin-embedded material. The applied antibodies had been
subjected to in-house validation by the manufacturer for
IHC analysis on paraffin-embedded material. The anti-
bodies used in the study were as follows: Phospho-Akt
(Ser473) (1:5; Rabbit monoclonal, clone 736E11; #3787;
Cell Signalling Technology, Danvers, U.S.A.), detects
Akt 1 only when phosphorylated at serine 473, and
Akt2 and Akt3 only when phosphorylated at equivalent
sites. Phospho-Akt (Thr308) (1:50; Rabbit monoclonal,
clone 244F9; #4056; Cell Signalling Technology), recog-
nizes all three Akt isoforms when phosphorylated at this
site. Akt2 (1:18; Rabbit monoclonal, clone 54G8; #4057;
Cell Signalling Technology), preferentially binds to non-
phosphorylated endogenous levels of Akt2. It does not
cross-react with recombinant Akt1 or Akt3. Akt3 (1:8;
Rabbit polyclonal, #4059; Cell Signalling Technology),
d e t e c t se n d o g e n o u sl e v e l so ft o t a lA k t 3 ,b u td o e sn o t
recognize the truncated form of rat Akt3. The antibody
does not cross-react with recombinant Akt1 or Akt2.
PTEN (1:10, Rabbit monoclonal; #9559; Cell Signalling
Technology), detects endogenous levels of total PTEN
protein. PI3K (1:25; Rabbit polyclonal; #4254; Cell Sig-
nalling Technology), detects endogenous levels of total
PI3K.
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drated with ethanol. Antigen retrieval was performed by
placing the specimen in 0.01mol/l citrate buffer at pH
6.0 and exposed to two repeated microwave heatings of
10 minutes at 450W. The DAKO EnVision + System-
HRP (DAB) kit was used as endogen peroxidase block-
ing. Primary antibodies were incubated overnight at 4°C
(except PI3K, for 32 minutes at room temperature). The
DAKO EnVision+ System-HRP (DAB) kit was used to
visualize the antigens for all stains. This yielded a brown
reaction product at the site of the target antigen. As
negative staining controls, the primary antibodies were
replaced with the primary antibody diluent. Finally, all
slides were counterstained with hematoxylin to visualize
the nuclei. For each antibody, including negative con-
trols, all TMA staining were performed in one single
experiment. The immunohistochemical staining for ER
and PgR was performed as described earlier[25].
Scoring of IHC
The ARIOL imaging system (Genetix, San Jose, CA) was
used to scan the slides with immunohistochemically
stained TMAs. The specimens were scanned at a low
resolution (1.25×) and high resolution (20×) using
Olympus BX 61 microscope with an automated platform
(Prior). The slides were loaded in the automated slide
loader (Applied Imaging SL 50). Representative and
viable tissue sections were scored manually on computer
screen, semiquantitatively for cytoplasmic staining for
PI3K/Akt pathway components and for nuclear staining
for ER and PgR. The dominant staining intensity in neo-
plastic cells was scored subjectively as: 0 = negative; 1 =
weak; 2 = intermediate; 3 = strong (Figure 1). For ER
and PgR, the modified All Red scoring system [25] was
used. All samples were anonymized and independently
scored by two pathologists (A.V. and S.S.). In cases
where score difference was equal to or exceeding 2, the
slides were re-examined and a consensus was reached
by the observers. When assessing a score for a given
core, the observers were blinded to the scores of the
other variables and to outcome. Mean score for dupli-
cate cores from each individual was calculated.
Statistical methods
All statistical analyses were done using the statistical
package SPSS (Chicago, IL), version 16. The IHC scores
from each observer were compared for interobserver
reliability by use of a two-way random effect model with
absolute agreement definition. The intraclass correlation
coefficient (reliability coefficient) was obtained from
these results. The Chi-square test and Fishers Exact test
were used to examine the association between molecular
marker expression and various clinicopathological para-
m e t e r s .U n i v a r i a t ea n a l y s e sw e r ed o n eb yu s i n gt h e
Kaplan-Meier method, and statistical significance
between survival curves was assessed by the log rank
test. Disease-specific survival (DSS) was determined
from the date of histological confirmed STS diagnosis to
the time of STS death. To assess the independent value
of different pretreatment variables on survival, in the
presence of other variables, multivariate analysis was
performed using the Cox proportional hazards model.
Only variables with value 0.10 or less from the univari-
ate analysis were entered into the Cox regression analy-
sis. The significance level used in both univariate and
multivariate analyses was P < 0.05, but in the post hoc
subgroup analysis the significance level was moved from
P = 0.05 to P = 0.01 due to risk of false positivity.
Ethical clearance
The National Cancer Data Inspection Board and The
Regional Committee for Research Ethics approved the
study. The Regional Committee approved that written
consent from the patients for their information to be
stored in the hospital database and used for research
was not needed because most of the material was more
than 20 years old and most of the patients are now
dead. The material was collected from our approved
biobank for paraffin-embedded material and slides. All
material was anonymously collected. The data were ana-
lyzed anonymously.
Results
Clinicopathological variables
The clinicopathological variables are summarized in Table
1. Median age was 59 (range, 0-91) years and 56% were
female. The non-GIST STS comprised 249 tumors includ-
ing pleomorphic sarcoma (n = 68), leiomyosarcoma (n =
67), liposarcoma (n = 34), malignant fibroblastic/myofibro-
blastic tumors (n = 20), rhabdomyosarcoma (n = 16),
synovial sarcoma (n = 16), angiosarcoma (n = 13), malig-
nant peripheral nerve sheath tumor (MPNST) (n = 11)
and other types of sarcoma (n = 4). The tumors were loca-
lized in the extremities (n = 89), viscera (n = 58), trunk (n
= 47), retroperitoneum (n = 37) and head/neck (n = 18).
The treatment option of choice was surgery (n = 228), 120
patients received surgery alone, 55 patients received sur-
gery and radiotherapy, 40 patients received surgery and
chemotherapy and13 patients received surgery, radiother-
apy and chemotherapy. Of the non-operated patients
(inoperable, n = 11; advanced age/other serious disease, n
= 5, STS diagnosis confirmed post mortem, n = 3; patient
refusal, n = 2) seven received chemotherapy and/or radio-
therapy. Fourteen patients did not obtain any treatment.
Interobserver variability
Interobserver scoring agreement was tested for all mar-
kers. The intraclass correlation coefficients were as
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Page 3 of 12follows: 0.89 for p-Akt Ser
473 (p < 0.001), 0.94 for p-Akt
Thr
308 (p < 0.001), 0.91 for Akt2 (p < 0.001), 0.95 for
Akt3 (p < 0.001), 0.88 for PI3-K (p < 0.001) and 0.89 for
PTEN (p < 0.001).
Expression pattern and correlations with
clinicopathological variables
In the immunohistochemical analyses, we used antibo-
dies against all Akt isoforms, including Akt phosphory-
l a t e da tS e r
473 and at Thr
308, non-phosphorylated Akt2
and total (both phosphorylated and non-phosphorylated)
Akt3. Besides, we investigated expression of total PI3K
and PTEN. The p-Akt Ser
473, p-Akt Thr
308, Akt2, Akt3,
PI3K and PTEN showed expression in the cytoplasm or
both in the cytoplasm and in the nuclei of tumor cells
in the majority of cases, while pure nuclear staining was
demonstrated in a smaller proportion of the tumors,
varying from 7% of all immunohistochemically positive
tumors for PTEN to 19% for p-Akt Thr
308 and Akt3.
Expression of p-Akt Ser
473 (r = 0.179, P = 0.005), p-
Akt Thr
308 (r = 0.150, P = 0.019), Akt2 (r = 0.250, p <
0.001) and PI3K (r = 0.223, p < 0.001) correlated signifi-
cantly positive with STS histological grade. PI3K and p-
Akt Thr
308 positivity in STSs correlated with presence
Figure 1 IHC analysis of TMA of non-GIST STS representing different expressions of markers belonging to PI3K/Akt pathway in tumor
cells. A, Leiomyosarcoma, histological grade I, PTEN, negative staining, score 0; B, Pleomorphic liposarcoma, histological grade III, p-Akt Thr
308,
weak nuclear staining, score 1; C, Undifferentiated pleomorphic sarcoma, histological grade III, PI3K, moderate cytoplasmic staining; score 2; D,
Dedifferentiated liposarcoma, histological grade II, p-Akt Ser
473, strong both nuclear and cytoplasmic staining, score 3. All calibration bars
correspond to 100 μm in the overview images (objective 10×) and 50 μm in the pictures taken at high magnification (objective 40×).
Abbreviations: IHC, immunohistochemistry; TMA, tissue microarray; non-GIST STS, non gastro-intestinal stromal tumor soft-tissue sarcoma; PTEN,
phosphatase and tensin homolog; p-Akt Thr
308, Akt phosphorylated at threonin 308; PI3K, phosphoinositide 3-kinase; p-Akt Ser
473, Akt
phosphorylated at serin 473.
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analyses, log-rank test).
Characteristic Patients
(n)
Patients
(%)
Median survival
(months)
5-Year survival
(%)
P
Age
≤ 60 years 133 53 59 50 0.065
> 60 years 116 47 30 40
Gender
Male 110 44 41 46 0.390
Female 139 56 45 45
Patient nationality
Norwegian 167 67 63 51 0.011
Russian 82 33 22 34
Histological entity
Pleomorphic sarcoma 68 27 29 40 0.102
Leiomyosarcoma 67 27 45 46
Liposarcoma 34 14 NR 67
MF/MFT 20 8 43 50
Angiosarcoma 13 5 10 31
Rhabdomyosarcoma 16 6 17 38
MPNST 11 5 49 45
Synovial sarcoma 16 6 31 29
Other STSs 4 2 NR 18
Tumor localization
Extremities 89 36 100 53 0.348
Trunk 47 29 32 44
Retroperitoneum 37 25 25 38
Head/Neck 18 7 15 41
Visceral 58 23 30 42
Tumor size
≤ 5 cm 74 30 127 57 0.027
5-10 cm 91 37 44 45
>1 0c m 8 1 3 2 2 8 3 6
Missing 3 1
Malignancy grade
1 61 25 NR 74 <0.001
29 8 3 9 4 1 4 5
39 0 3 6 1 6 2 6
Tumor depth
Superficial 17 7 NR 93 <0.001
Deep 232 93 36 42
Metastasis at the time of diagnosis
No 206 83 76 53 <0.001
Yes 43 17 10 10
Surgery
Yes 228 92 59 50 <0.001
No 21 8 5 0
Resection margins
Free 178 71 127 66 <0.001
Not free/no surgery 71 29 10 18
Chemotherapy
No 191 77 52 47 0.424
Yes 58 23 29 40
Radiotherapy
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of p-Akt Thr
308 was observed in 69% of the metastasiz-
ing tumors, whereas only 41% of non-metastasizing
STSs (r = 0.208, P = 0.001) were strongly positive for
this marker. For PI3K, the metastasizing versus non-
metastasizing characteristics comprised 78% and 53%,
respectively (r = 0.188, P = 0.003). None of the investi-
gated markers correlated significantly with age, gender,
tumor location, depth, size or relapse rate.
Univariate analyses
Data are presented in Table 1. Patient nationality (P =
0.011), tumor size (P = 0.027), malignancy grade (p <
0.001), tumor depth (p < 0.001), metastasis at time of
diagnosis (p < 0.001), surgery (p < 0.001) and resection
margins (p < 0.001) were all significant prognostic vari-
ables for DSS.
The prognostic impact of the investigated molecular
factors is shown in Table 2. Among these, p-Akt Thr
308
(P = 0.002), Akt2 (P = 0.008) and PI3K (p < 0.001) were
significant indicators of shorter DSS, Figure 2, A-C.
In order to find out whether subcellular location of
proteins belonging to the Akt/PI3K signaling pathway
has impact on survival, we performed a series of univari-
ate analyses to compare the impact of their expression
in nucleus, cytoplasm or both. Nuclear expression of p-
Akt Thr
308 expression showed a significantly favorable
prognosis (P = 0.029), compared to cytoplasmic and
Table 1 Clinicopathological variables as predictors for disease-specific survival in 249 non-GIST STSs (univariate ana-
lyses, log-rank test). (Continued)
No 176 71 48 46 0.590
Yes 73 29 38 43
Abbreviations: non-GIST STS, non-gastro intestinal stromal tumor soft-tissue sarcoma; NR, not reached; MF/MFT, malignant fibroblastic/myofibroblastic tumors;
MPNST, malignant peripheral nerve sheath tumor
Table 2 Tumor expression of markers belonging to PI3K/Akt signaling pathway and their prognostic impact on
disease-specific survival in patients with non-GIST STSs (univariate analyses; log-rank test, n = 249), for all patients
and separately for men and women.
Marker expression Patients, n (%) Median survival
(months)
5-Year survival (%) P
AMW A M W A M W A M W
p-Akt Thr
308
Low 131(53) 59 (55) 72 (52) 91 NR 80 55 56 54 0.002 0.009 0.064
High 113 (45) 48 (44) 65 (47) 29 26 31 35 33 36
Missing 5 (2) 3 (1) 2 (1)
p-Akt Ser
473
Low 70 (28) 35 (32) 35 (25) 62 41 127 51 45 57 0.074 0.868 0.023
High 174 (70) 74 (67) 100 (72) 31 41 29 43 46 40
Missing 5 (2) 1 (1) 4 (3)
Akt2
Low 82 (33) 41 (37) 41 (39) 123 NR 80 58 56 59 0.008 0.062 0.064
High 163 (65) 68 (62) 95 (68) 31 31 31 41 42 40
Missing 4 (2) 1 (1) 3 (3)
Akt3
Low 177 (71) 81 (74) 96 (69) 62 63 57 51 51 50 0.067 0.207 0.197
High 60 (24) 22 (20) 38 (27) 31 27 38 35 33 36
Missing 12 (5) 7 (6) 5 (4)
PI3K
Negative 104 (42) 44 (40) 60 (43) NR NR 127 60 57 63 <0.001 0.078 <0.001
Positive 136 (56) 61 (55) 75 (54) 29 37 23 37 41 33
Missing 9 (4) 5 (5) 4 (3)
PTEN
Negative 88 (35) 37 (34) 51 (37) 80 NR 80 51 51 51 0.259 0.658 0.198
Positive 148 (59) 67 (61) 81 (58) 41 41 38 46 48 44
Missing 13 (6) 5 (5) 7 (5)
Abbreviations: Non-GIST STS, non-gastro intestinal stromal tumor soft-tissue sarcoma; A, all; M, men; W, women; NR, not reached
Valkov et al. Journal of Translational Medicine 2011, 9:200
http://www.translational-medicine.com/content/9/1/200
Page 6 of 12especially mixed cytoplasmic and nuclear expression,
Figure 2, D. The other factors did not show any signifi-
cant prognostic differences in the subcellular location.
Subgroup analysis based on clinical variables revealed
that high expression of both p-Akt Thr
308 (P = 0.006)
and Akt3 (P = 0.001) were adverse prognostic indicators
for STSs located to extremities and for tumors larger
than 5 cm in largest dimension (P = 0.001 for both mar-
kers). Interestingly, high expression of p-Akt Thr
308 was
an e g a t i v ep r o g n o s t i cf a c t o rp a r t i c u l a r l yf o rm e n( P=
0.009 vs. P = 0.064 for women). In contrast, p-Akt
Ser
473, which appeared to be a negative prognosticator
exclusively for female patients (P = 0.023 vs. P = 0.868
for men), Table 2.
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Figure 2 Disease-specific survival curves for the investigated markers, their expression pattern and coexpression with steroid
hormone receptors. A, p-Akt Thr
308; B, Akt2; C, PI3K; D, p-Akt Thr
308, by cellular expression pattern; E, p-Akt Ser
473 in coexpression with ER, men;
F, p-Akt Ser
473 in coexpression with ER, women. Abbreviations: p-Akt Thr
308, Akt phosphorylated at threonin 308; PI3K, phosphoinositide 3-kinase;
p-Akt Ser
473, Akt phosphorylated at serin 473; ER, estrogen receptor.
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The results of the multivariate analysis are presented in
Table 3. Advanced age of the patient (P = 0.038), deep
site (P = 0.018), high malignancy grade (p < 0.001),
metastasis at time of diagnosis (P = 0.010), lack of sur-
gery (P = 0.031), non-free resection margins (p < 0.001),
and PI3K expression by tumor cells (P = 0.042) were
significant independent negative prognostic indicators of
DSS.
Co-expression of activated Akt and PI3K with female
steroid hormone receptors
The co-expression profiles of both types of activated Akt
and PI3K with female steroid hormone receptors, in the
group as a whole and stratified into gender were tested
as shown in Table 4. The co-expression phenotypes PgR
+/p-Akt Thr
308+ among men (P = 0.023, HR = 2.4, 95%
CI = 1.1-5.2), ER-/PI3K+ both in whole cohort (P =
0.005, HR = 2.0, 95% CI = 1.2-3.2) and among women
(P = 0.014, HR = 2.4, 95% CI = 1.2-4.8), as well as
PgR-/PI3K+ (P = 0.007, HR = 1.9, 95% CI = 1.2-3.0)
and PgR+/PI3K+ (P = 0.014, HR = 1.9, 95% CI = 1.1-
3.2) in the whole cohort of patients were significant
independent negative prognostic factors. Interestingly,
both steroid hormone receptors and Akt phosphoryla-
tion site seem to have opposite prognostic impact
depending on the gender. This was further proved by
the co-expression of these factors. Indeed, PgR-/p-Akt
Ser
473+ phenotype tended to have an unfavorable impact
in women (P = 0.087) but was favorable in men (P =
0.010). Co-expression of ER and p-Akt Ser
473 showed
similar results, with significantly adverse influence of -/+
profile on DSS among female patients (P = 0.006).
There was no significant difference among the four pos-
sible profiles in men, but the -/+ curve demonstrated
the best survival rate, Figure 2E and 2F.
Discussion
In this large-scale retrospective study we have investi-
gated the prognostic impact of a set of biomarkers
belonging to the Akt-PI3K signaling pathway in non-
GIST STS patients, both separately and in relation to
gender. Further, we have also elucidated the coexpression
of these markers and the female hormone receptors ER
and PgR. These proteins participate in a diversity of pro-
cesses in physiological and pathological conditions, espe-
cially in cancer development and progression [14]. p-Akt
Thr
308, Akt2 and PI3K showed significant unfavorable
influence on survival of the whole cohort of patients in
univariate analyses and, in addition, high expression of
PI3K was a significant independent negative prognostic
factor. p-Akt Thr
308 expression had a strong unfavorable
impact among men, but was not significant in women. p-
Akt Ser
473 expression had strong adverse impact in
w o m e nb u tw a sn o ts i g n i f i c a n ti nm e no ri nt h ew h o l e
cohort. PgR-/p-Akt Ser
473+ phenotype showed less favor-
able impact in women, but was the most favorable one in
men. To our knowledge, this is the first prognostic eva-
luation of these biomarkers in non-GIST STSs.
Akt, aka protein kinase B, is a serine/threonine protein
kinase. Currently, three mammalian isoforms (Akt1/
PKBa,A k t 2 / P K B b,a n dA k t 3 / P K B g)h a v eb e e ni d e n t i -
fied. They are encoded by different genes and have dif-
ferent tissue distribution [29].
In a healthy organism, Akt1 is a key signaling protein in
the cellular pathways that result in skeletal muscle hyper-
trophy, and general tissue growth [30]. Akt can be phos-
phorylated by its two activating kinases, phosphoinositide
dependent kinase 1 (PDK1) - at threonine
308, and mam-
malian target of rapamycin complex 2 (mTORC2), pre-
viously putatively named PDK2, - at serine
473.B o t h
mTORC2 and PDK1 are products of the PI3K pathway.
Activated Akt can activate or deactivate its multiple sub-
strates, including mammalian target of rapamycin
(mTOR), bcl-2 family member BAD, transcription factor
forkhead homolog 1 in rhabdomyosarcoma (FKHR),
Mdm2 protein, glycogen synthase kinase 3 (GSK3) and
many others, via its kinase activity [31,32].
Table 3 Results of the Cox regression analysis
summarizing significant independent prognostic factors
in the overall material.
Factor Hazard Ratio 95% CI P
Age
≤60 1.0
>60 1.5 1.0-2.1 0.038
Tumor depth
Superficial 1.0
Deep 11 1.5-79 0.018
Malignancy grade <0.001*
1 1.0
2 2.4 1.3-4.2 0.003
3 3.7 2.1-6.6 <0.001
Metastasis at the time of diagnosis
No 1.0
Yes 1.9 1.2-3.1 0.010
Surgery
Yes 1.0
No 2.2 1.1-4.4 0.031
Resection-margins
Free 1.0
Non-free 2.5 1.6-3.8 <0.001
PI3K
Negative 1.0
Positive 1.5 1.0-2.2 0.042
Abbreviations: PI3K, phosphoinositide-3-kinase.
* Overall significance as a prognostic factor
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Page 8 of 12Table 4 Co-expression of activated AKT and PI3K with ER and PGR and their prediction for DSS in patients with non-
GIST STSs (univariate analyses; log-rank test, n = 249, only significant combinations are represented) and results of
Cox regression analysis (multivariate analyses).
Univariate analyses Multivariate analyses
Markers
coexpression
Patients
(n)
Patients
(%)
Median survival
(months)
5-Year survival
(%)
P Hazard ratio 95% CI P
ER/p-Akt Thr
308 all
-/- 83 33 127 57 0.002 NS
-/+ 58 23 18 29
+/- 42 17 63 54
+/+ 47 19 45 46
Missing 19 8
ER/p-Akt Thr
308 women
-/- 42 30 57 50 0.012 NS
-/+ 35 25 16 27
+/- 27 19 91 59
+/+ 25 19 120 53
Missing 11 7
PgR/p-Akt Thr
308 all
-/- 101 41 127 59 0.014 NS
-/+ 62 25 26 38
+/- 26 10 54 46
+/+ 49 20 32 32
Missing 11 4
PgR/p-Akt Thr
308 men
-/- 49 45 NR 64 0.003 1.0 0.099*
-/+ 30 27 29 43 2.0 1.0-4.1 0.047
+/- 8 7 15 25 1.8 0.65-4.8 0.261
+/+ 17 16 17 18 2.4 1.1-5.2 0.023
Missing 6 5
ER/p-Akt Ser
473 women
-/- 18 13 127 63 0.006 NS
-/+ 58 41 16 32
+/- 14 10 62 56
+/+ 37 27 91 55
Missing 13 9
PgR/p-Akt Ser
473 men
-/- 29 27 NR 55 0.010 1.0 0.022*
-/+ 51 47 NR 57 1.1 0.54-2.4 0.744
+/- 4 4 21 0 6.7 1.9-24 0.003
+/+ 21 19 15 24 1.5 0.67-3.2 0.329
Missing 5 5
ER/PI3K all
-/- 65 27 127 60 0.002 1.0 0.032*
-/+ 73 29 18 36 2.0 1.2-3.2 0.005
+/- 33 13 NR 63 1.1 0.56-2.1 0.816
+/+ 56 22 37 43 1.4 0.83-2.4 0.200
Missing 22 9
ER/PI3K women
-/- 33 24 100 59 <0.001 1.0 0.036*
-/+ 42 30 15 25 2.4 1.2-4.8 0.014
+/- 23 16 NR 70 0.9 0.36-2.0 0.715
+/+ 29 21 29 46 1.5 0.72-3.0 0.290
Missing 13 9
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biting apoptotic processes. Since it thereby promotes
cell survival, Akt1 has been regarded as a major factor
in many types of cancer [15-17]. The majority of studies
agree that high expression of Akt by tumor cells indi-
cates a poor prognosis [19-21]. However, in a recent
study by Baba et al., phosphorylated Akt expression was
reported to have a favorable impact on DSS in 717 col-
orectal cancer patients [22]. Similar results were
obtained by Mori et al. in a study devoted to Akt
expression in endometrial carcinoma [23]. This discre-
pancy can probably be explained by the site of Akt
phosphorylation. Both studies utilized antibodies against
p-Akt Ser
473, while the articles describing negative influ-
ence of Akt are based on p-Akt Thr
308 expression
[20,33,34]. Al-Saad et al. [33] has recently compared the
prognostic impact of Akt phosphorylated on both sites
a n dd e m o n s t r a t e dt h a te x p r e s s i o no fp - A k tT h r
308,
unlike p-Akt Ser
473, negatively influenced prognosis in
patients with non-small cell lung cancer.
For the whole cohort we also found that p-Akt Thr
308
expression was associated with a shorter STS survival in
univariate analyses, while p-Akt Ser
473 expression had
no significant value. However, calculated separately for
each gender, high expression of p-Akt Thr
308 was a
negative prognostic factor particularly for men, in con-
trast to p-Akt Ser
473, which appeared to be a negative
prognosticator exclusively for female patients. This
prompted us to further investigate this phenomenon by
studying of co-expression profiles of both types of acti-
vated Akt with female steroid hormone receptors. In
our previous works we have shown that ER and PgR
expression possess variable prognostic significance
depending of gender both per se [25] and in co-expres-
sion with TGF-b and fascin [26]. ERb was shown to
activate PI3K/Akt signalling pathway [35]. Tsai et al.
demonstrated an activation of Akt by estrogen in ER
negative breast cancer cell culture [36]. In the present
study, the prognostic diversity of these factors in men
and women was enhanced in the co-expression profiles:
male patients with STSs expressing simultaneously p-
Akt Thr
308 and PgR had statistically significant minimal
survival rate. For women, the ER-/p-Akt Ser
473+ expres-
sion profile was the most unfavorable phenotype.
Taking into consideration a possible distortion of the
results by gender-related sarcomas (i.e. leiomyosarcoma
in uterus) we have attempted to exclude these sarcomas
and recalculate all analyses. There were no considerable
differences in the results by exclusion of gender-related
sarcomas comparing to those obtained for whole cohort
(data not shown).
Akt2 is an important molecule in the insulin signaling
pathway, but in Akt1 deficient mice it is also proved to
substitute, at least partly, the role of Akt1 in growth and
proliferation [37]. We found Akt2 expression to be asso-
ciated with significantly shorter DSS in univariate analy-
sis. This might be explained by the extra-endocrine
function of Akt2. The role of Akt3 is less clear, it
Table 4 Co-expression of activated AKT and PI3K with ER and PGR and their prediction for DSS in patients with non-
GIST STSs (univariate analyses; log-rank test, n = 249, only significant combinations are represented) and results of
Cox regression analysis (multivariate analyses). (Continued)
PgR/PI3K all
-/- 76 31 NR 62 0.001 1.0 0.032*
-/+ 86 35 29 43 1.9 1.2-3.0 0.007
+/- 26 10 100 58 1.3 0.69-2.5 0.397
+/+ 46 18 31 27 1.9 1.1-3.2 0.014
Missing 15 6
PgR/PI3K men
-/- 36 34 NR 65 0.014 NS
-/+ 44 40 63 51
+/- 7 6 21 29
+/+ 15 14 17 20
Missing 7 6
PgR/PI3K women
-/- 40 29 80 59 0.007 NS
-/+ 42 30 17 36
+/- 19 14 NR 68
+/+ 31 21 31 31
Missing 8 6
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; NR, not reached; NS, not significant;
* overall significance as a prognostic factor
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Page 10 of 12appears to be predominantly expressed in the central
nervous system [29]. In this study, we failed to demon-
strate any association of Akt3 with the survival of STS
patients.
PI3K is, via PDK1 and mTORC2 dependent activation,
an upstream regulator of all Akt isoforms, and plays an
important role in the PI3K/Akt pathway. Its high
expression has been implicated as an adverse prognostic
factor in many types of cancer [38-40]. In STS, we
observed that PI3K expression was an independent sig-
nificant indicator of shorter DSS. Not surprisingly, the
co-expression of PI3K with both ER and PgR showed
multiple independent negative impacts on survival in
STS patients with the phenotypes ER-/PI3K+ in women
and PgR+/PI3K+ in men being the least favorable.
The tumor suppressor gene PTEN negatively regulates
the PI3K/Akt signaling pathway. It is a proapoptotic and
antineoplastic factor and shown to be a favorable prog-
nosticator in cancer patients [41]. In our study, we failed
to find any statistical difference in survival between
patients having PTEN-positive and PTEN-negative STSs.
In our material, all investigated factors showed three
distinct patterns of expression; nuclear, cytoplasmic and
combined nuclear and cytoplasmic. Little is known
about the prognostic value of such subcellular stratifica-
tion. Le Page et al. reported that nuclear Akt-1 and Akt-
2 expression were significantly correlated with favorable
outcome in 63 prostate cancer patients, while cytoplas-
mic Akt-1 expression was correlated with a higher risk
of postoperative prostate-specific antigen (PSA) recur-
rence and shorter PSA recurrence interval [42]. In the
present study, we were able to find such dependence
only for nuclear p-Akt Thr
308 expression, which proved
to be prognostically favorable compared to cytoplasmic
and especially mixed cytoplasmic and nuclear location.
Conclusion
We have characterized the occurrence and distribution
of several proteins belonging to PI3K/Akt signaling
pathway in STS patients with respect to tumor aggres-
siveness and DSS. Our findings are largely in agreement
with the results of a number of studies that have investi-
gated the roles of these markers in other, especially
epithelial, tumors. Nevertheless, the diverse prognostic
values depending on the site of Akt phosphorylation
and on the co-expression with female steroid hormones
have not been described earlier.
Our findings may help to identify subgroups of
patients with aggressive tumors requiring adjuvant ther-
apy which, due to relationship of the PI3K/Akt pathway
components with female steroid hormone receptor pro-
teins, could include specific endocrine treatment. More-
over, since the investigated biomarkers belong to the
family of serine-threonine kinases, which are
comprehended as “drugable”[18], they may represent
molecular targets for personalized, small-molecule tar-
geted therapy. This currently is a hotspot of oncological
research, and it was shown effect of such Akt targeted
agents on several subtypes of sarcomas in vitro [43,44].
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